Craving. Mental and behavioural disorders due to use of opioids withdrawal state
Conditions
Interventions
Intervention 1: celecoxib capsule 200 mg orally daily for 1 month. Intervention 2: ibuprofen, soft gel capsule 400 mg four times daily up to 1 month.
Treatment - Drugs
celecoxib capsule 200 mg orally daily for 1 month
ibuprofen, soft gel capsule 400 mg four times daily up to 1 month
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Age range 18-65; not using other NSAIDs during the trial; having abused opiates for at least six months Exclusion criteria: pregnancy; lactation; suffering serious physical illnesses such as cancer, cardiovascular diseases, respiratory, cerebrovascular diseases and any thyroid disorder including Hypo or hyperthyroidism; People with other axis I psychiatric disorders and intellectual disability.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Craving. Timepoint: At baseline and 4 weeks after the initiation of the study. Method of measurement: Drug Desire Questionnaire (DDQ). | — |
Secondary
| Measure | Time frame |
|---|---|
| Pain. Timepoint: At baseline and 4 weeks after the initiation of the study. Method of measurement: 0-10 numeric pain rating scale.;Other side effects of treatments. Timepoint: after 4 weeks of treatment. Method of measurement: Side Effect Check List. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDoctor Sara Jafari
Roozbeh Hospital
Outcome results
None listed